Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald Radich

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|January 11, 2005
Increased AF1q gene expression in high-risk myelodysplastic syndromeWilliam Tse, H Joachim Deeg, Derek Stirewalt, et al.
Leukemia Research|May 5, 2009
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemiaKoyu Hoshino, Alfonso Quintás-Cardama, Jerald Radich, et al.
JAMA Network Open|April 30, 2025
Oncologist-Patient Concordance and Treatment Adherence in Chronic Myeloid LeukemiaJ Felipe Montano-Campos, Erin E Hahn, Eric C Haupt, et al.
Leukemia & Lymphoma|April 25, 2019
A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantationEvandro D Bezerra, Mary E Flowers, Lynn E Onstad, et al.
Leukemia Research and Treatment|January 20, 2016
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisUrsula Rochau, Martina Kluibenschaedl, David Stenehjem, et al.
Plos One|March 17, 2022
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemiaDawne N Shelton, Prasanthi Bhagavatula, Nathan Sepulveda, et al.
Blood Reviews|December 30, 2019
The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemiaJan Philipp Bewersdorf, Rory M Shallis, Prajwal C Boddu, et al.
Scientific Reports|August 29, 2025
MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa, EthiopiaFekadu Urgessa, Isaac Jenkins, Aster Tsegaye, et al.
Nature Reviews. Cancer|April 3, 2003
The case for early detectionRuth Etzioni, Nicole Urban, Scott Ramsey, et al.
BMC Cancer|April 25, 2024
Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional studyFekadu Urgessa, Boki Lengiso, Aster Tsegaye, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|January 11, 2005
Increased AF1q gene expression in high-risk myelodysplastic syndromeWilliam Tse, H Joachim Deeg, Derek Stirewalt, et al.
Leukemia Research|May 5, 2009
Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemiaKoyu Hoshino, Alfonso Quintás-Cardama, Jerald Radich, et al.
JAMA Network Open|April 30, 2025
Oncologist-Patient Concordance and Treatment Adherence in Chronic Myeloid LeukemiaJ Felipe Montano-Campos, Erin E Hahn, Eric C Haupt, et al.
Leukemia & Lymphoma|April 25, 2019
A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantationEvandro D Bezerra, Mary E Flowers, Lynn E Onstad, et al.
Leukemia Research and Treatment|January 20, 2016
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisUrsula Rochau, Martina Kluibenschaedl, David Stenehjem, et al.
Plos One|March 17, 2022
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemiaDawne N Shelton, Prasanthi Bhagavatula, Nathan Sepulveda, et al.
Blood Reviews|December 30, 2019
The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemiaJan Philipp Bewersdorf, Rory M Shallis, Prajwal C Boddu, et al.
Scientific Reports|August 29, 2025
MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa, EthiopiaFekadu Urgessa, Isaac Jenkins, Aster Tsegaye, et al.
Nature Reviews. Cancer|April 3, 2003
The case for early detectionRuth Etzioni, Nicole Urban, Scott Ramsey, et al.
BMC Cancer|April 25, 2024
Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional studyFekadu Urgessa, Boki Lengiso, Aster Tsegaye, et al.
Pageof 10